Eli Lilly’s Bold Pricing Move Sparks Investor Debate

Having recently surpassed the historic $1 trillion market capitalization milestone, pharmaceutical titan Eli Lilly now faces pressure on its share price. The catalyst is a bold strategic shift: implementing significant price reductions for its blockbuster weight-loss drug, Zepbound. This aggressive move has left market participants questioning whether the company is sacrificing profitability for market dominance or strategically igniting a new phase of expansion.

In a direct challenge to Danish rival Novo Nordisk, Eli Lilly has launched substantial price cuts for Zepbound on its LillyDirect platform. The monthly cost for the 2.5-mg single-dose pen has been reduced from $349 to $299. An even steeper discount applies to the 5-mg dose, which now costs $399, down Read more...